Shares of Hims & Hers Health Inc. climbed sharply in morning trading Friday as investors bet that potential regulatory relief on compounded peptides could strengthen the telehealth company's weight-loss offerings and broader platform growth.
At 11:15 a.m. EDT, Hims & Hers stock (NYSE: HIMS) traded at $28.50, up 5.59 percent or $1.51 on the session, extending gains from Thursday's 11 percent surge. The move came amid high volume and renewed enthusiasm for the company's position in personalized health and wellness amid evolving Food and Drug Administration policies.
